These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 38480630)

  • 1. Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability.
    Carlson AK; Amin M; Cohen JA
    Drugs; 2024 Mar; 84(3):285-304. PubMed ID: 38480630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis.
    Cotchett KR; Dittel BN; Obeidat AZ
    Mult Scler Relat Disord; 2021 Apr; 49():102787. PubMed ID: 33516134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20-Yet Progress Continues.
    Frisch ES; Pretzsch R; Weber MS
    Neurotherapeutics; 2021 Jul; 18(3):1602-1622. PubMed ID: 33880738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management.
    Alvarez E; Longbrake EE; Rammohan KW; Stankiewicz J; Hersh CM
    Mult Scler Relat Disord; 2023 Nov; 79():105009. PubMed ID: 37783194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis.
    Bar-Or A; O'Brien SM; Sweeney ML; Fox EJ; Cohen JA
    CNS Drugs; 2021 Sep; 35(9):985-997. PubMed ID: 34370283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ublituximab: A new FDA-approved anti-CD20 mAb for relapsing forms of multiple sclerosis.
    Boldrini VO; Mader S; Kümpfel T; Meinl E
    Mult Scler Relat Disord; 2023 Jul; 75():104733. PubMed ID: 37156035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting CD20 in multiple sclerosis - review of current treatment strategies.
    Chmielewska N; Szyndler J
    Neurol Neurochir Pol; 2023; 57(3):235-242. PubMed ID: 36999373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis.
    Sellebjerg F; Blinkenberg M; Sorensen PS
    CNS Drugs; 2020 Mar; 34(3):269-280. PubMed ID: 31994023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date.
    Ancau M; Berthele A; Hemmer B
    Expert Opin Biol Ther; 2019 Aug; 19(8):829-843. PubMed ID: 31027436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocrelizumab and Other CD20
    Gelfand JM; Cree BAC; Hauser SL
    Neurotherapeutics; 2017 Oct; 14(4):835-841. PubMed ID: 28695471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic.
    de Sèze J; Maillart E; Gueguen A; Laplaud DA; Michel L; Thouvenot E; Zephir H; Zimmer L; Biotti D; Liblau R
    Front Immunol; 2023; 14():1004795. PubMed ID: 37033984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic Review of Safety and Efficacy of Second- and Third-Generation CD20-Targeting Biologics in Treating Immune-Mediated Disorders.
    Kaegi C; Wuest B; Crowley C; Boyman O
    Front Immunol; 2021; 12():788830. PubMed ID: 35185862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ofatumumab for relapsing forms of multiple sclerosis.
    Gajofatto A; Orlandi R
    Drugs Today (Barc); 2022 Jan; 58(1):9-21. PubMed ID: 35107090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ublituximab-xiiy as a treatment option for relapsing multiple sclerosis.
    Jakimovski D; Weinstock-Guttman B; Zivadinov R
    Expert Rev Neurother; 2023; 23(12):1053-1061. PubMed ID: 37842819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapies for multiple sclerosis targeting B cells.
    Milo R
    Croat Med J; 2019 Apr; 60(2):87-98. PubMed ID: 31044580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B cell depletion in the treatment of multiple sclerosis.
    Myhr KM; Torkildsen Ø; Lossius A; Bø L; Holmøy T
    Expert Opin Biol Ther; 2019 Mar; 19(3):261-271. PubMed ID: 30632834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment.
    Delgado SR; Faissner S; Linker RA; Rammohan K
    J Neurol; 2024 Apr; 271(4):1515-1535. PubMed ID: 37906325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [B-cell depletion in the therapy of multiple sclerosis: ofatumumab is a new player].
    Pukoli D; Vécsei L
    Ideggyogy Sz; 2022 May; 75(5-06):163-169. PubMed ID: 35819344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment.
    Hauser SL; Kappos L; Bar-Or A; Wiendl H; Paling D; Williams M; Gold R; Chan A; Milo R; Das Gupta A; Karlsson G; Sullivan R; Graham G; Merschhemke M; Häring DA; Vermersch P
    Neurol Ther; 2023 Oct; 12(5):1491-1515. PubMed ID: 37450172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis : Immunotherapy with rituximab, ocrelizumab, and ofatumumab.
    Ovchinnikov A; Findling O
    Wien Med Wochenschr; 2022 Nov; 172(15-16):359-364. PubMed ID: 35723820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.